SecBot SecBot
8-K ·Filed Apr 9, 2026

FBRX

Forte Biosciences, Inc.
NEUTRAL
Impact 5/10
Horizonimmediate Processed7mo ago SEC0001193125-26-148796
8-K material event: Items 1.01
Actionable Insight • Neutral

Monitor for potential stock price pressure from the dilution of new shares, though the strategic investment by argenx BV may provide some offsetting support. The capital infusion strengthens the company's position to advance its clinical programs.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$33.90
T+0 close · Apr 9, 2026 · via day close
Latest settled
−39.79%
T+60 · $20.41
Vs SPY
−50.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 9 $33.90entry
  2. T+1 · 7mo ago +3.51%α +3.57% · $35.09
  3. T+5 · 7mo ago −7.29%α −10.47% · $31.43
  4. T+20 · 6mo ago −21.77%α −29.34% · $26.52
  5. T+60 · 4mo ago −39.79%α −50.58% · $20.41
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Forte Biosciences announced a $150 million public offering of 5.7 million shares at $26.27 per share, with a 30-day option for underwriters to purchase an additional 856,490 shares. Concurrently, argenx BV made a strategic investment in the company. The proceeds will fund clinical development and general corporate purposes.

Key Financial Metrics

Deal Value
$150.0M

Key Facts

  • Forte Biosciences priced a public offering of 5,709,936 shares at $26.27 per share
  • Underwriters have a 30-day option to purchase up to an additional 856,490 shares
  • Gross proceeds expected to be approximately $150 million before underwriting discounts and commissions
  • Net proceeds estimated at $141 million ($162 million if full option exercised), to be used for clinical development and general corporate purposes
  • Strategic investment made by argenx BV as part of the offering

Financial Impact

Raises approximately $141 million in net proceeds (up to $162 million if full option exercised), diluting existing shareholders

dilutioncashdebt

Risk Factors

  • Dilution from new share issuance could pressure stock price
  • Market conditions could affect the successful closing of the offering
  • Execution risk in clinical development despite additional funding

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-148796
Document: d128424d8k.htm0001193125-26-148796
Document: d128424dex51.htm0001193125-26-148796
Document: d128424dex991.htm0001193125-26-148796
Document: 0001193125-26-148796-index-headers.html0001193125-26-148796
Document: 0001193125-26-148796-index.html0001193125-26-148796
Document: 0001193125-26-148796.txt0001193125-26-148796

Track record

15 reports on FBRX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +39.79% at T+60 after the Apr 8, 2026 report. 4 of 7 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  3. Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
  4. Sep 2, 202610w ago EFFECT Bearish 7/10 Entry $76.99 settles Nov 27
  5. Sep 2, 202610w ago EFFECT Bearish 6/10 Entry $76.99 settles Nov 27
  6. Aug 27, 202611w ago 25-NSE Bearish 9/10 Entry $76.99 settles Nov 20
  7. Jul 27, 202616w ago 8-K Bullish 8/10 Entry $76.50 No price data
  8. Jun 11, 202622w ago EFFECT Bearish 6/10 Entry $17.40 No price data
  9. Jun 5, 202623w ago S-3/A Bearish 6/10 Entry $15.67 No price data
  10. Jun 2, 202623w ago S-3 Bearish 6/10 Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (10h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 9, 2026